New immuno-oncology therapies that direct the immune system to identify and destroy cancer cells have revolutionized cancer treatment.
Antibodies can increase the engagement of immune and tumor cells stimulating killing, by direct cytotoxicity or phagocytosis.
Cell engineering approaches to create T and NK cells to seek and destroy cancer offer vast potential, with the first of these cell-based therapies receiving regulatory approval.
Therefore, a deeper understanding of immune/tumor cell interactions and processes leading to cancer cell eradication is critical to identify and validate new targets and therapeutic approaches.
Key webinar discussion topics include:
- Illustration of the use of advanced high throughput flow cytometry to detect immune cell cytotoxicity with a variety of applications and model immunotherapeutics
- Discussion of immune cell killing assays such as NK cell cytotoxicity
- Explanation of how to implement antibody dependent cytotoxicity and antibody dependent cellular phagocytosis assays
- Description of how advanced high throughput flow cytometry addresses bottlenecks in the development of biologics and cell-based therapies